| Fiscal period | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|
| Period End Date | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 |
|---|
| Sales | 1,374.72 | 1,307.02 | 1,244.74 | 1,045.47 | 1,010.64 | 862.46 | 955.10 | 859.63 | 796.39 | 763.52 |
| Total Revenues | 1,374.72 | 1,307.02 | 1,244.74 | 1,045.47 | 1,010.64 | 862.46 | 955.10 | 859.63 | 796.39 | 763.52 |
| Cost of sales | 624.25 | 573.98 | 568.50 | 474.23 | 442.60 | 402.16 | 430.38 | 390.52 | 365.35 | 355.19 |
| Gross Profit | 750.48 | 733.03 | 676.25 | 571.25 | 568.04 | 460.30 | 524.72 | 469.11 | 431.04 | 408.33 |
| Impairment of goodwill | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Research and development expense | 55.88 | 54.43 | 52.60 | 47.15 | 43.57 | 40.47 | 45.46 | 42.19 | 32.31 | 32.25 |
| Selling and administrative expense | 591.97 | 478.28 | 503.04 | 454.04 | 414.75 | 373.82 | 400.14 | 355.62 | 351.80 | 338.40 |
| Other expense (income) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Write-off of purchased in-process research and development assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Medical device excise tax | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Operating Expenses | 647.85 | 532.71 | 555.64 | 501.19 | 458.32 | 414.29 | 445.60 | 397.81 | 384.11 | 370.65 |
| Income (loss) from operations | 102.62 | 200.33 | 120.60 | 70.05 | 109.72 | 46.01 | 79.11 | 71.31 | 46.94 | 37.68 |
| Interest expense | 31.09 | 37.30 | 39.78 | 28.91 | 35.49 | 44.05 | 42.70 | 20.65 | 18.20 | 15.36 |
| Impairment of goodwill | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain (loss) on early extinguishment of debt | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Amortization of debt discount | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other expense | (0.42) | -- | -- | (112.01) | (1.13) | (0.36) | (5.19) | -- | -- | (2.94) |
| Income (loss) before income taxes | 71.12 | 163.03 | 80.83 | (70.86) | 73.11 | 1.60 | 31.23 | 50.65 | 28.73 | 19.38 |
| Provision for income taxes | 24.06 | 30.61 | 16.37 | 9.72 | 10.56 | (7.91) | 2.61 | 9.80 | (26.76) | 4.71 |
| Current- Federal | 5.73 | -- | 2.07 | 0.10 | (0.10) | (0.73) | 0.10 | (1.08) | 1.74 | 0.31 |
| Current- State | 2.05 | -- | 3.83 | 1.58 | 0.61 | 0.09 | 0.44 | 0.78 | 2.10 | 0.16 |
| Current - Foreign | 12.75 | -- | 9.78 | 14.08 | 7.05 | 6.96 | 8.38 | 8.04 | 9.42 | 7.11 |
| Deferred income tax expense | -- | -- | -- | -- | -- | -- | -- | 2.06 | (40.02) | (2.87) |
| Deferred income tax expense (benefit): Federal | -- | -- | 2.83 | (4.10) | 3.47 | (12.25) | (3.97) | -- | -- | -- |
| Deferred income tax expense (benefit): State | -- | -- | (0.89) | (1.64) | 1.45 | (1.17) | (0.94) | -- | -- | -- |
| Deferred income tax expense (benefit): Foreign | -- | -- | (1.23) | (0.31) | (1.91) | (0.81) | (1.40) | -- | -- | -- |
| Income before extraordinary loss | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Extraordinary loss, net of income taxes | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Income (Loss) Available to Common Shareholders | 47.06 | 132.42 | 64.46 | (80.58) | 62.54 | 9.52 | 28.62 | 40.85 | 55.49 | 14.66 |
| Income before extraordinary loss - (Basic) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Extraordinary loss - (Basic) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Basic) | 1.52 | 4.29 | 2.10 | (2.68) | 2.14 | 0.33 | 1.01 | 1.45 | 1.99 | 0.53 |
| Income before extraordinary loss (Diluted) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings Per Share (Diluted) - Extras | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Diluted) | 1.51 | 4.25 | 2.04 | (2.68) | 1.94 | 0.32 | 0.97 | 1.41 | 1.97 | 0.52 |
| Weighted Average Shares Outstanding (Basic) | 31.04 | 30.85 | 30.67 | 30.04 | 29.16 | 28.58 | 28.33 | 28.12 | 27.94 | 27.80 |
| Weighted Average Shares Outstanding (Diluted) | 31.15 | 31.15 | 31.55 | 30.04 | 32.22 | 29.46 | 29.50 | 28.89 | 28.17 | 27.96 |